Pulmonary tuberculosis in Guinea-Bissau: Clinical and bacteriological findings, human immunodeficiency virus status and short term survival of hospitalized patients

Tubercle and Lung Disease

Volumn 77, Issue 3, 1996, Pages 226-232

  Naucler A ^a   Winqvist, N ^b   Dias, F ^c   Koivula, T ^c   Lacerda, L ^d   Svenson, S B ^a   Biberfeld, G ^a   Norberg, R ^a   Kallenius G ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b MAS   (Sweden)

^c Lab Nac de Saude Pub   (Guinea-Bissau)

^d Hospital Raoul Follereau   (Guinea-Bissau)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL EXAMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GUINEA-BISSAU; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLOTTING; LUNG TUBERCULOSIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; SPUTUM CYTODIAGNOSIS; SURVIVAL; WEIGHT REDUCTION;

EID: 0029785245     PISSN: 09628479     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8479(96)90005-2     Document Type: Article

References (22)

1. Rieder H L et al. Epidemiology of tuberculosis in the United States. Epidemiol Rev 1989; 11: 79-98.
2. Selwyn P A et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. New Engl J Med 1989; 320: 545-550.
3. Nunn P P, McAdam K P W J. Mycobacterial infection and AIDS. Br Med Bull 1988; 44: 801-813.
4. McLeod D T et al. Pulmonary diseases in patients infected with the human immunodeficiency syndrome in Zimbabwe, Central Africa. Trans Royal Soc Trop Med Hygiene 1989; 83: 691-697.
5. Mbaga J M et al. Survival time of patients with acquired immune deficiency syndrome: experience with 274 patients in Dar-Es-Salaam. East Afr Med J 1990; 67: 95-99.
6. Tsega E. The demographic, social and clinical presentations of one hundred Ethiopian patients with human immunodeficiency virus (HIV) infection. Ethiop Med J 1990; 28: 81-88.
7. De Cock K M, Gnaore E, Adjorlolo G et al. Risk of tuberculosis in patients with HIV-I and HIV-II infections in Abidjan, Ivory Coast. Br Med J 1991; 302: 496-499.
8. Ancelle R, Bletry O, Baglin A C, Brun-Vezinet F, Rey M A, Godeau P. Long incubation period for HIV-2 infection. Lancet 1987; i: 688-689.
9. Pepin J, Morgan G, Dunn D, et al. HIV-2-induced immunosuppression among asymptomatic West African prostitutes: evidence that HIV-2 is pathogenic, but less so than HIV-1. AIDS 1991; 5: 1165-1172.
10. De Cock K M, Brun Vézinet F. Epidemiology of HIV-2 infection. AIDS 1989; 3 (suppl 1): S89-95.89.
11. Nauclér A, Andreasson P A, Mendes Costa C, Thorstensson R, Biberfeldt G. HIV-2-associated AIDS and HIV-2 seroprevalence in Bissau, Guinea-Bissau. J Acquir Immune Defic Syndr 1989; 2: 88-93.
12. Nauclér A, Albino P, da Suva A P, Andreasson P A, Andersson S, Biberfeld G. HTV-2 infection in hospitalized patients in Bissau, Guinea-Bissau. AIDS 1991; 5: 301-304.
13. Poulsen A G, Kvinnesdal B, Aaby P et al. Prevalence and mortality from human immunodeficiency virus type 2 in Bissau, West Africa. Lancet 1989; i: 827-830.
14. World Health Organization. Case definition for AIDS. Wkly Epidemiol Rec 1986; 61: 69-76.
15. European Society for Mycobacteriology. In: Groothuis D G, Yates M D, eds Manual of Diagnostic and Public Health Mycobacteriology, 2nd ed, Bureau of Hygiene and Tropical Diseases. 1991.
16. Hoffner S E, Svenson S B, Norberg R, Dias F, Ghebremichael S, Källenius G. Biochemical heterogeneity of Mycobacterium tuberculosis complex isolates in Guinea-Bissau. J Clin Microbiol 1993; 31: 2215-2217.
17. Kent, Kubica. Public Health Mycobacteriology. A Guide for the Level III Laboratory. Centers for Disease Control. 1985.
18. Albert J, Bredberg-Rådén U, Chiodi F et al. A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II and HTLV-IIIB. AIDS Res Hum Retroviruses 1987; 3: 3-10.
19. World Health Organization. Proposed WHO criteria for interpreting results from Western blot assays for HIV-1, HIV-2 and HTLV-I/HTLV-II. WHO Wkly Epidemiol Rec 1990; 37: 281-283.
20. Böttiger B, Karlsson A, Nauclér A et al. Envelope cross reactivity between human immunodeficiency virus type 1 and 2 detected by different serological methods: correlation between cross neutralisation and reactivity against the main neutralizing site. J Virol 1990; 64: 3492-3499.
21. Colebunders R L, Braun M M, Nzila N, Dikilu K, Muepu K, Ryder R. Evaluation of the World Health Organization clinical case definition of AIDS among tuberculosis patients in Kinshasa, Zaire. J Infect Dis 1989; 160: 902-903.
22. Dias F, Ghebremichael S, Hoffner S E, Martins L, Norberg R, Källenius G. Drug susceptibility in Mycobacterium tuberculosis of a sample of patients in Guinea Bissau. Tubercle Lung Dis 1993; 74: 129-130.